美通社

2024-12-06 08:07

Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO HT Install at Hong Kong Center for Neurodegenerative Diseases

FREMONT, Calif., Dec. 6, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce its commercial presence in the Asia Pacific (APAC) region with the installation of the ARGO™ HT System, an advanced ultra-sensitive proteomics platform, at the prestigious Hong Kong Center for Neurodegenerative Diseases (HKCeND). The ARGO HT System along with the NULISA™ Platform are designed to revolutionize biomarker discovery by enabling researchers to detect and quantify proteins at unprecedented levels of sensitivity and accuracy.

Hong Kong Center for Neurodegenerative Diseases
Hong Kong Center for Neurodegenerative Diseases

"Expansion of the ARGO HT installed base to the APAC region represents a significant step forward in our vision to bring transformative proteomics solutions to researchers worldwide," said Dr. Yuling Luo, Founder, Chairman and CEO of Alamar Biosciences. "We are excited to contribute to HKCeND's vibrant scientific community and support groundbreaking advancements in the fight against neurodegenerative diseases."

Prof. Nancy Ip, the Director of Hong Kong Center for Neurodegenerative Diseases (HKCeND), added, "The integration of the NULISA Technology enabled by the ARGO HT System into our research infrastructure is a game-changer. This technology will allow us to explore the proteomic underpinnings of neurodegenerative diseases in ways that were previously unimaginable."

The partnership with HKCeND will focus on unlocking new insights into the molecular mechanisms of neurodegenerative diseases such as Alzheimer's disease, and Parkinson's disease. The ARGO HT System and NULISA Platform deployments will empower HKCeND's researchers to identify novel biomarkers, accelerate drug development, and improve early detection and personalized treatment strategies for patients.

About Alamar Biosciences, Inc.

Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.

About Hong Kong Center for Neurodegenerative Diseases
The Hong Kong Center for Neurodegenerative Diseases (HKCeND) is a leading research institution dedicated to advancing the understanding and treatment of neurodegenerative disorders. By fostering interdisciplinary collaborations and leveraging state-of-the-art technologies, HKCeND aims to make transformative contributions to global neuroscience.

Alamar's ARGO HT System installed at the Hong Kong Center for Neurodegenerative Diseases
Alamar's ARGO HT System installed at the Hong Kong Center for Neurodegenerative Diseases

 


source: Alamar Biosciences, Inc.

【你點睇】陳美寶、羅淑佩分別被任命為運物局及文體旅局局長,你是否認同新任命有助香港鞏固物流樞紐地位及促進旅遊經濟?► 立即投票

人氣文章
財經新聞
評論
專題
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【etnet30周年連環賞】睇住賞Maxcare美天復康寶(升級版) (價值HK$1,680)

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

回顧24 展望25

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watche Trends 2024

北上食買玩

Artcation

秋冬養生食療

消委會報告

山今養生智慧

輕鬆護老